Instrument Inactif

Communiqués Clarus Therapeutics Holdings, Inc.

Actions

CRXT

US18271L1070

Produits pharmaceutiques

Communiqués

01/03/23	CLARUS THERAPEUTICS HOLDINGS, INC. : Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Other Events (form 8-K)	AQ
22/02/23	CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
24/01/23	CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
22/12/22	CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
23/11/22	CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
31/10/22	CLARUS THERAPEUTICS HOLDINGS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
24/10/22	CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
18/10/22	CLARUS THERAPEUTICS HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
18/10/22	Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder	GL
15/09/22	CLARUS THERAPEUTICS HOLDINGS, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)	AQ
06/09/22	Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code	GL
26/08/22	CLARUS THERAPEUTICS HOLDINGS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
19/08/22	CLARUS THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
18/08/22	CLARUS THERAPEUTICS HOLDINGS, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
18/08/22	Clarus Therapeutics : Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction - Form 8-K	PU
18/08/22	Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction	AQ
10/08/22	Clarus Therapeutics : Management Change/Compensation - Form 8-K	PU
09/08/22	CLARUS THERAPEUTICS HOLDINGS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
28/07/22	Clarus Therapeutics Announces Notice of Allowance for Additional Patent Claims Covering JATENZO® (testosterone undecanoate)	AQ
15/06/22	CLARUS THERAPEUTICS HOLDINGS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
09/06/22	CLARUS THERAPEUTICS HOLDINGS, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
09/06/22	Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting	AQ
18/05/22	Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate)	AQ
16/05/22	CLARUS THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
16/05/22	Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results	AQ